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There is natural enrichment of NK cells in the human liver and this intrahepatic
predominance underscores their potential importance in the control of infections with
hepatotropic viruses such as hepatitis B virus (HBV).The contribution of innate components
during chronic HBV infection has been a relatively under-investigated area. However, recent
data have highlighted that NK cells are capable of exerting antiviral and immunoregulatory
functions whilst also contributing to the pathogenesis of liver injury via death receptor path-
ways. We will present an overview of current knowledge regarding the complex biology of
NK cells in the context of their antiviral versus pathogenic role in chronic hepatitis B as a
clinically relevant avenue for further investigation.
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INTRODUCTION
The study of NK cells during infection with the hepatotropic
hepatitis B virus (HBV) provides a useful opportunity to con-
sider the function of these important immune effector cells within
the unique liver environment. Despite the availability of a pre-
ventative vaccine, HBV continues to cause persistent infection in
an estimated 400 million people worldwide. The virus itself is
non-cytopathic, but triggers immune responses resulting in per-
sistent inflammation and progressive fibrosis in the infected liver.
These immune-mediated pathological processes ultimately lead to
cirrhosis and hepatocellular carcinoma, resulting in more than a
million HBV-related deaths annually. Although the introduction
of new antiviral agents with a high genetic barrier to resistance
has improved the treatment of HBV, sustained cure rates are still
low (Papatheodoridis et al., 2008). The inherent capacity of the
immune system to efficiently contain HBV in acutely infected
adults who resolve infection provides a strong rationale for the
development of new treatments based on immunotherapeutic
boosting. However, this requires a careful dissection of the mul-
tifaceted immune response, to identify which components can be
harnessed to control viremia and/or its pathological consequences
without exacerbating disease. Here we will consider the current
evidence in favor of protective or pathogenic roles for NK cells in
HBV infection.
NK CELLS IN CONTEXT: THE LIVER MICROENVIRONMENT
In order to understand the role of NK cells in HBV infection it
is necessary to first consider some specialized features of the liver
microenvironment, well-known for its tolerogenic properties. This
state of “immune privilege” prevents an overwhelming response to
the innocuous antigens that the liver is constantly exposed to from
the gastrointestinal tract, but provides an advantageous setting
for those pathogens able to infect the liver to establish chronic-
ity. Hepatic tolerance is maintained by a number of aspects of
the local immunological environment including the cytokine and
nutrient milieu, and influences of the target hepatocytes and other
specialized resident cell types (Crispe, 2009; Protzer et al., 2012).
NK cell biological function is tightly regulated by the balance
of signals provided by their diverse array of cell surface receptors,
combined with the cytokine milieu. In the liver, their activation
is likely to by heavily influenced by the ligands they encounter
on the cells lining the extensive sinusoidal network (Figure 1A).
The potential for liver sinusoidal endothelial cells and Kupffer cells
(sinusoidal-resident macrophages) to display relevant NK cell lig-
ands is an area just beginning to be investigated. For example
Tim-3, upregulated on NK cells in chronic HBV infection (CHB),
can down-modulate their function (Ju et al., 2010); its ligand,
galectin-9, is strongly expressed by Kupffer cells (Nebbia et al.,
2012). Kupffer cells also have the potential to influence NK cells
through their cytokine production; they are one of many intrahep-
atic cell types able to produce immunosuppressive cytokines such
as IL-10 and TGF-β that can tolerize local NK cells (Tu et al., 2008),
as discussed further below. NK cells can in addition make direct
contact with infected hepatocytes, either through fenestrations in
the sinusoidal lining or after migrating into the parenchyma. Thus
intrahepatic NK cell function may be further shaped by the bal-
ance of signals received from hepatocytes, with their very low levels
of MHC Class I but potential to upregulate cellular stress ligands
(Chen et al., 2007).
One of the most striking differences between the immune com-
position of the liver and the blood is the proportion of NK cells.
In the healthy liver, the percentage of NK is typically increased
more than threefold compared to the periphery, accounting for
around a third of the intrahepatic mononuclear cell population
(Doherty et al., 1999). Liver NK cells also show phenotypic and
functional characteristics that are distinct from their circulating
counterparts. In particular, intrahepatic NK cells are more acti-
vated and the majority have a CD56bright phenotype, thought to
be an earlier stage of differentiation than the CD56dim phenotype
predominating in the periphery (Burt et al., 2009; Shi et al., 2011).
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FIGURE 1 | (A) Potential influences of the hepatic milieu on NK cells.
The liver sinusoidal endothelial network is extensive and narrow, with
sluggish blood flow encouraging intimate contact between circulating
and resident cell types. NK cells are exposed to a milieu rich in IL-10 and
TGF-β and can interact with ligands on a number of specialized resident
liver cells such as galectin-9 on Kupffer cells and NKG2D on
hepatocytes. They may also be influenced by inhibitory/stimulatory
ligands expressed by liver sinusoidal endothelial cells or stellate cells.
(B) Functions of NK cells in the HBV-infected liver. NK cells can utilize
death ligands to kill hepatocytes (contributing to liver damage) and
HBV-specific T cells (curtailing antiviral immunity). They exhibit impaired
non-cytolytic antiviral function (reduced IFN-γ production), but may
serve a protective function to limit liver fibrosis by killing activated
stellate (pro-fibrotic) cells.
Even the CD56dimCD16+ fraction of intrahepatic NK cells express
lower levels of KIRs than this subset in the periphery, which may
limit their capacity to be adequately licensed (Burt et al., 2009).
The fetal liver is a site of NK cell generation, raising the pos-
sibility that some NK cells arise in the adult liver, in line with
their immature phenotype. The derivation of adult intrahepatic
NK cells has been addressed by an interesting study document-
ing the rapid re-population of liver grafts with recipient NK cells
and their precursors (Moroso et al., 2011). These data suggest that
NK cell precursors derived from the bone marrow are recruited
from the circulation and take on the “signature” of hepatic NK
cells once resident in the liver. This hepatic NK cell enrichment is
maintained in the inflammatory infiltrate characteristic of HBV
infection (Sprengers et al., 2006; Dunn et al., 2007). The chemo-
tactic signals regulating the influx and retention of human hepatic
NK cells and NK cell precursors remain to be defined. Particularly
pertinent to this is the recent finding in murine models that the
chemokine receptor CXCR6 retains a population of NK cells in the
liver that mediate long-lived “memory” responses to viruses and
haptens (Paust et al., 2010).
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THE ANTIVIRAL ROLE OF NK CELLS IN HBV INFECTION
There is an accumulating body of evidence supporting an antivi-
ral role for NK cells, reinforced by the elaborate mechanisms
employed by a number of viruses for NK cell immune evasion
(Martin et al., 2002; Orange et al., 2002; Khakoo et al., 2004;
Lee et al., 2007). More recent studies have identified associations
between control of human persistent viral infections such as HIV
and HCV and particular genes for KIRs (a highly polymorphic
family of NK receptors) and the HLA molecules they interact with
(Martin et al., 2002; Khakoo et al., 2004). Associations between
KIRs and viral control may be the result of differential efficiency
of NK effector function (Alter et al., 2007); the idea that NK cells
can exert immune pressure on persistent viruses such as HIV is
supported by evidence of KIR-associated viral adaptation at a
population level (Alter et al., 2011).
NK cells have the capacity to exert antiviral activity in HBV
infection through direct effects or indirectly, by modulating T cell
responses. Whilst NK cells can promote T cell responses through
their production of cytokines like IFN-γ, emerging data are high-
lighting their capacity to conversely limit antiviral responses by
deletion or inhibition of T cells (Waggoner et al., 2010, 2012; Lang
et al., 2012). Direct NK cell effects could involve lysis of infected
hepatocytes through granzyme/perforin or death receptor path-
ways. However viral clearance through these mechanisms would
only be achieved at the expense of death of infected hepatocytes
(see section on liver damage below). Non-cytolytic mechanisms
of HBV clearance through cytokines like IFN-γ (Guidotti et al.,
1996) are therefore thought to play a critical role in mediating
viral control in the infected liver, whilst preserving the integrity
of this vital organ. The contribution of NK cells to these mecha-
nisms in the acutely and chronically HBV-infected liver remains
controversial.
The antiviral potential of NK cells has been demonstrated in
animal models of HBV infection, with NK cells efficiently inhibit-
ing HBV replication in transgenic mice (Kakimi et al., 2000) and
making a contribution to clearance in the hydrodynamic injec-
tion model of acute HBV (Yang et al., 2002). In chimpanzees,
NK cells were initially implicated by the finding that the first
phase of non-cytolytic clearance of HBV-infected hepatocytes
was accompanied by an increase in intrahepatic IFN-gamma and
TNF-alpha (Guidotti et al., 1999). However, subsequent experi-
ments showed a critical role for T cells rather than NK cells in
HBV control in this model (Thimme et al., 2003). Studies of
patients in the pre-clinical ramp-up phase of acute HBV infec-
tion revealed an increase in the number of circulating NK cells
(Webster et al., 2000; Fisicaro et al., 2009) but their activation
and effector function was suppressed as viral load increased and
only peaked once viremia had resolved (Dunn et al., 2009). This
inhibition of NK cell activation and effector potential showed
an inverse temporal correlation with induction of the immuno-
suppressive cytokine IL-10, raising the possibility that HBV can
actively evade immune responses (Dunn et al., 2009). No data
are available from humans immediately after HBV inoculation
regarding the involvement of NK cells before detectable viral
replication. However woodchucks infected with high doses of the
closely related woodchuck hepatitis virus showed upregulation of
the NK cell activating receptor NKp46 immediately after infection
(Guy et al., 2008), suggesting that NK cells may make their
major contribution to HBV control in the earliest lag phase of
infection.
In CHB, persistent, high-level viremia, and the tolerizing liver
environment combine to drive profound exhaustion of antiviral
T cells. In the presence of a disabled T cell response, ineffective
viral control, and ongoing liver inflammation, it is plausible that
the large number of activated NK cells could perform a compen-
satory antiviral function. However our recent data reveal that NK
cells in this setting instead play a key role in disarming adaptive
immunity. We observed that activated HBV-specific T cells, par-
ticularly those in the intrahepatic compartment, upregulate death
receptors that render them susceptible to elimination by NK cells
(Peppa et al., 2013; Figure 1B). Furthermore, we and other groups
have shown that NK cells in patients with CHB become defec-
tive in their production of IFN-γ (Oliviero et al., 2009; Peppa
et al., 2010; Tjwa et al., 2011), making them ineffective at exert-
ing direct non-cytolytic antiviral functions and at promoting T
cell responses. We postulated that this selective defect in NK cell
function may be attributable to the influence of IL-10 and TGF-β
in the liver, since it was restored following in vitro blockade of
these immunosuppressive cytokines (Peppa et al., 2010). IL-10 is
induced in flares of CHB (Das et al., 2012), as in acute infection,
and can recapitulate a selective defect in NK cell IFN-γ produc-
tion (Peppa et al., 2010). Evidence from murine models suggests
that these immunosuppressive cytokines may impair NK cell func-
tion by modifying their receptor expression. IL-10 was found to
contribute to the regulation of liver NK cells by maintaining a
higher percentage of the hyporesponsive NKG2A+Ly49− subset
of NK cells (Lassen et al., 2010). In patients with CHB, the partial
recovery of NK cell IFN-γ production upon antiviral therapy has
been linked to the downregulation of NKG2A (Tjwa et al., 2011).
Impaired functionality of NK cells in CHB has also been attributed
to the capacity of TGF-β to downregulate the NKG2D/DAP10 and
2B4/SAP pathways (Sun et al., 2012). In a further recent study,
HBV modulation of pDC–NK cell crosstalk was found to con-
tribute to impaired IFN-γ production by NK cells (Shi et al., 2012),
highlighting the importance of reciprocal interactions with other
innate cells.
PATHOGENIC ROLES OF NK CELLS IN THE HBV-INFECTED
LIVER
Hepatitis B virus is a non-cytopathic virus which mediates liver
disease by the immune responses it triggers. Elegant experiments
in the HBV transgenic mouse model demonstrated a role for the
non-specific infiltrate recruited in the liver at the time of peak
inflammation in acute hepatitis (Ando et al., 1993). Analogous
findings came from the study of livers from patients with persis-
tent HBV infection, in whom an infiltrate of non-antigen specific
lymphocytes was found to be associated with liver inflammation
(Maini et al., 2000). One of the largest constituents of the inflam-
matory infiltrate in HBV transgenic mice was NK1.1+CD3−
NK cells, with a 10- to 12-fold increase in their numbers com-
pared to baseline (Kakimi et al., 2001). An infiltration of NK
cells has been shown to be associated with Pseudomonas induced
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hepatotoxicity (Beraza et al., 2009), MCMV induced hepatitis in
mice (Salazar-Mather et al., 1998), and persistent HCV infection
(Nuti et al., 1998).
The large number of activated intrahepatic NK cells could
contribute to HBV-induced liver damage through a number of
effector mechanisms. As discussed above, circulating NK cells
preferentially maintain their cytolytic compared to non-cytolytic
capacity in HBV infection (Oliviero et al., 2009; Peppa et al.,
2010). Intrahepatic NK cells have been less thoroughly stud-
ied in this regard but a recent study has suggested that they
are likewise biased to cytotoxicity in patients with active HBV-
related inflammation compared to those with no biochemical
evidence of liver damage, or to healthy controls (Zhang et al.,
2011). However some studies suggest hepatocytes may be rela-
tively resistant to perforin/granzyme-mediated cytotoxicity (Tay
and Welsh, 1997; Kafrouni et al., 2001) and mouse models have
supported a role for death ligands from the TNF superfamily
in mediating liver damage through the induction of hepato-
cyte apoptosis (Galle et al., 1995; Balkow et al., 2001; Zheng
et al., 2004). Hepatocyte apoptosis is increasingly recognized to
play a part in the initiation of hepatic inflammation (Malhi
and Gores, 2008); this is likely to be particularly relevant in the
context of CHB since infected apoptotic cells have been shown
to instruct an immunogenic rather than tolerogenic immune
response (Stockinger, 2009).
One death ligand implicated in liver damage is TRAIL (Zheng
et al., 2004), which murine liver NK cells were originally noted to
express in the setting of tumor metastases (Takeda et al., 2001).
Human NK cells were reported to express minimal amounts of
TRAIL in both the circulation and liver of healthy individuals
(Ishiyama et al., 2006), but work from our lab revealed that NK
cells could upregulate this ligand in the setting of HBV-related
liver inflammation (Dunn et al., 2007). Unlike NK cell capacity
for the production of cytokines and cytotoxic mediators, which
vary according to the in vitro stimulus employed to elicit their
production, the expression of death ligands such as TRAIL could
be assessed directly ex vivo. TRAIL was found to be most highly
expressed on the CD56bright subset of NK cells that is preferen-
tially expanded and activated in the liver. A death receptor for
TRAIL, TRAIL-R2 (DR5), which had been previously thought to
be restricted to tumor tissue, was found to be upregulated on the
surface of hepatocytes in liver biopsies from patients with CHB.
NK cells from patients with HBV-related liver inflammation but
not from healthy controls,were able to induce apoptosis of primary
human hepatocytes. Blocking studies suggested this was partially
attributable to TRAIL but pointed to the involvement of additional
pathways (Dunn et al., 2007).
The Fas pathway has previously been implicated in hepato-
cyte apoptosis and HBV-related liver disease (Ogasawara et al.,
1993; Galle et al., 1995). A more recent study provided evidence
that DC-activated NK cells are capable of inducing HBV-infected
hepatocyte degeneration in a humanized mouse model through
the Fas/FasL system (Okazaki et al., 2012). Supporting a role for Fas
mediated liver injury, the expression of FasL on NK cells in HBV
patients correlated with progression of acute-on-chronic liver fail-
ure (Zou et al., 2010). However, a direct role for NK cells mediating
liver damage via the Fas pathway has not been fully established in
human infection with HBV. NK cells are also a potent source of
TNF, a pro-inflammatory cytokine that has been shown to aug-
ment liver injury (Mizuhara et al., 1994). Hepatic TNF and TNFR1
expression are enhanced in CHB (Mizuhara et al., 1994; Fang et al.,
1996), but again the capacity of these interactions to kill hepato-
cytes, and the involvement of NK cells, remains to be demonstrated
in CHB.
An interesting area requiring further dissection is how the
complex array of activatory and inhibitory NK cell receptors,
the cytokine milieu, and viral factors combine to regulate these
potential pathways of liver damage and viral elimination. Major
activatory NK cell receptors like NKG2D and NKp46 are likely to
play a key role in directing NK cell function in CHB. In support
of this, a recent study knocking down multiple NKG2D ligands
on hepatocytes was able to protect against fulminant hepati-
tis (Huang et al., 2013). In the case of the TRAIL pathway, we
found that IFN-α was able to potently upregulate NK cell ligand
expression (Dunn et al., 2007), in line with subsequent studies
suggesting that this is a major mechanism of action of therapeu-
tic IFN-α in the setting of HBV (Micco et al., 2013) and HCV
(Stegmann et al., 2010; Ahlenstiel et al., 2011). The enhancement
of NK cell effector function during IFN-α treatment was associ-
ated with an induction of NKp46 expression (Micco et al., 2013).
The cytokines IL-2 (Ishiyama et al., 2006) and IFN-γ (Tu et al.,
2008) have also been shown to be able to induce TRAIL, with
a recent study demonstrating a role for monocyte-derived IFN-
γ in driving NK cell TRAIL expression (Sarhan et al., 2012).
The sensitivity of hepatocytes to TRAIL-mediated apoptosis is
controlled by NEMO, the regulatory subunit of the IKK com-
plex mediating NF-kappaB activation (Beraza et al., 2009) and
can be enhanced by their upregulation of death-inducing recep-
tors, that may be promoted by IL-8 (Dunn et al., 2007), TGF-β
(Saitou et al., 2005), and HBV proteins (Janssen et al., 2003;
Liang et al., 2007). Likewise, susceptibility of hepatocytes to TNF-
induced death has recently been shown to be modulated by viral
infection, which sensitizes them to caspase-mediated apoptosis
induction (Wohlleber et al., 2012). TNF can also cooperate with
FasL to induce hepatocyte apoptosis by activating Bim and Bid
(Schmich et al., 2011). Taken together, these studies suggest that
NK cell-mediated liver damage requires a combination of fac-
tors enhancing NK cell activation with others able to sensitize
hepatocytes.
CONCLUSION: PROMOTING PROTECTIVE ROLES OF
NK CELLS IN THE HBV-INFECTED LIVER
Activated NK cells are abundant in the HBV-infected liver and
may play a role in early viral containment. With the progression
of chronic infection, NK cells, like T cells, are subjected to the
tolerizing effects of hepatic ligands and cytokines, skewing them
toward functional defects that limit their antiviral efficacy (Peppa
et al., 2010; Figure 1B). Conversely, NK cells are well-placed to
mediate pathogenic functions in CHB, promoting liver damage
(Dunn et al., 2007), and further constraining antiviral immunity
by deleting HBV-specific T cells (Peppa et al., 2013). However,
blocking key mediators of such effects would not be without risk
since it appears that NK cells may utilize these same pathways to
exert important protective effects in the liver.
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NK cells have been shown to limit fibrosis in rodent models
by killing stellate cells (the major hepatic profibrogenic popula-
tion) in a TRAIL and NKG2D-dependent manner (Radaeva et al.,
2006). A recent study supported this role for NK cells in HCV
and suggested that the anti-fibrotic effects of IFN-α therapy may
be partially attributable to its potential to boost NK cell-mediated
killing of stellate cells (Glassner et al., 2012). Hepatic NK cells may
also be able to produce IL-22, which has the capacity to be hepato-
protective, limiting tissue damage (Zenewicz et al., 2007). It will
be important to investigate whether subsets of NK cells in CHB
serve anti-fibrotic and/or hepatoprotective functions. Recent data
also point to a critical role for NK cells in tumor protection in the
setting of CHB (Kamimura et al., 2012), where the development
of hepatocellular carcinoma is a major threat.
Further studies are required to better understand the factors
triggering and mediating the opposing roles of NK cells in CHB
to allow these to be successfully exploited for therapeutic target-
ing. Dissecting pathways of human hepatic NK cell development
and education will increase our understanding of the mecha-
nisms involved in shaping NK cell responsiveness in the liver.
Future attempts to manipulate NK cell immunity in the setting
of hepatotropic viral infections would need to be carefully timed
and tailored to block pathogenic effects whilst harnessing vital
protective functions.
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